Menopause and bone density issues for women with epilepsy

Neurology

Volumn 61, Issue 6 SUPPL. 2, 2003, Pages

  Harden, Cynthia L ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM; CARBAMAZEPINE; COLLAGEN TYPE 1; ESTROGEN; PARATHYROID HORMONE; PHENOBARBITAL; PHENYTOIN; PROCOLLAGEN; PROGESTERONE; VALPROIC ACID; VITAMIN D;

ADULT; AGED; ANTICONVULSANT THERAPY; BONE DENSITY; BONE METABOLISM; CALCIUM METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; ESTROGEN DEFICIENCY; FEMALE; HIP FRACTURE; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; MENOPAUSE; MENSTRUAL CYCLE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; VERTEBRA FRACTURE; VITAMIN D METABOLISM;

EID: 0141542589     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.61.6_suppl_2.s16     Document Type: Review

References (39)

1. Valmadrid C, Voorhees C, Litt B, Schneyer C. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001;58:1369-1374.
2. Hailey D, Sampietro-Colom L, Marshall D, Rico R, Granados A, Asua J. The effectiveness of bone density measurement and associated treatments for prevention of fractures. An international collaborative review. Int J Tech Assess Health Care 1998;14:237-254.
3. Marshall D, Johnell O, Wedel H. Meta-analysis of well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-1259.
4. Lane JM, Russell L, Khan SN. Osteoporosis. Clin Orthop 2000;372:139-150.
5. Hahn TJ, Birge SJ, Scharp CR, Avioli LV. Phenobarbital-induced alterations in vitamin D metabolism. J Clin Invest 1972;51:741-748.
6. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA. Long-term anticonvulsant therapy leads to low bone mineral density - evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000;108:37-43.
7. Parfitt AM, Simon LS, Villanueva AR, Simon SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2:427-436.
8. Risteli J, Elmaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-640.
9. Koch HV, Kraft D, von Herrath D. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 1972;13:829-841.
10. Hahn TJ, Scharp CR, Richardson CA, Halstead LR, Kahn AJ, Teitelbaum SL. Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro. J Clin Invest 1978;62:406-414.
11. Stephen LJ, McLellen AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999;8:339-342.
12. Pluskiewicz W, Nowakowska J. Bone status after long-term anticonvulsant therapy in epileptic patients: evaluation using quantitative ultrasound of calcaneus and phalanges. Ultrasound Med Biol 1997;23:553-558.
13. Valimaki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994;9:631-637.
14. Filardi S, Guerreiro CA, Magna LA, Marques Neto JF. Bone mineral density, vitamin D and anticonvulsant therapy. Arq Neuropsiquiatr 2000;58:616-620.
15. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-449.
16. Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-1353.
17. Pedrera JD, Canal ML, Carvajal J, et al. Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. Eur J Clin Invest 2000;30:895-899.
18. Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999;99:269-275.
19. Annegers JF, Melton LJ III, Sun CA, Hauser WA. Risk of age-related fractures in patients with unprovoked seizures. Epilepsia 1989;30:348-355.
20. Lidgren L, Walloe A. Incidence of fracture in epileptics. Acta Orthop Scand 1977;48:356-361.
21. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:767-773.
22. Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002;43:768-772.
23. van Staa TP, Leufkens HG, Cooper C. Utility of medical and drug history in fracture risk prediction among men and women. Bone 2002;31:508-514.
24. Rosciszewska D. Menopause in women and its effects on epilepsy. Neurol Neurochir Pol 1978;12:315-319.
25. Abbasi F, Krumholz A, Kittner SJ, Langenberg P. Effects of menopause on seizures in women with epilepsy. Epilepsia 1999;40:205-210.
26. Harden CL, Pulver MC, Jacobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999;40:1402-1407.
27. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997;38:1082-1088.
28. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocrine Rev 1999;20:279-307.
29. Klein P, Herzog AG. Hormonal effects on epilepsy in women. Epilepsia 1998;39(suppl 8):S9-16.
30. Woolley CS, Schwartzkroin PA. Hormonal effects on the brain. Epilepsia 1998;39(suppl 8):S2-8.
31. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81:1495-1501.
32. Felson DT, Zhang Y, Hanna MT, Kiel DP, Wilson PW, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density of elderly women. N Engl J Med 1993;329:1141-1146.
33. Wood AJ. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-1071.
34. Mayeaux EJ, Johnson C. Current concepts in postmenopausal hormone replacement therapy. J Fam Pract 1996;43:69-75.
35. Lafferty FW, Fiske ME. Postmenopausal estrogen replacement: a long-term cohort study. Am J Med 1994;97:66-77.
36. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
37. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: Principal results of the Women's Health Initiative randomized, controlled trial. JAMA 2002;288:321-333.
38. Klein P, Serje A, Pezzullo JC. Premature ovarian failure in women with epilepsy. Epilepsia 2001;42:1584-1589.
39. Harden C, Labar D, Koppel B, et al. Factors influencing the age at menopause in women with epilepsy. Epilepsia 2002;43(suppl 7):231-232.